80 related articles for article (PubMed ID: 19328289)
1. PDE4 inhibitors - a review of the current field.
Press NJ; Banner KH
Prog Med Chem; 2009; 47():37-74. PubMed ID: 19328289
[No Abstract] [Full Text] [Related]
2. PDE4 inhibitors: a review of current developments (2005 - 2009).
Pagès L; Gavaldà A; Lehner MD
Expert Opin Ther Pat; 2009 Nov; 19(11):1501-19. PubMed ID: 19832118
[TBL] [Abstract][Full Text] [Related]
3. Rhodanine derivatives as novel inhibitors of PDE4.
Irvine MW; Patrick GL; Kewney J; Hastings SF; MacKenzie SJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):2032-7. PubMed ID: 18304812
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
5. Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system.
Nanda K; Chatterjee M; Arya R; Mukherjee S; Saini KS; Dastidar S; Ray A
Biotechnol J; 2008 Oct; 3(9-10):1276-9. PubMed ID: 18655041
[TBL] [Abstract][Full Text] [Related]
6. Tetomilast.
O'Mahony S
IDrugs; 2005 Jun; 8(6):502-7. PubMed ID: 15906198
[TBL] [Abstract][Full Text] [Related]
7. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans.
Bian H; Zhang J; Wu P; Varty LA; Jia Y; Mayhood T; Hey JA; Wang P
Biochem Pharmacol; 2004 Dec; 68(11):2229-36. PubMed ID: 15498513
[TBL] [Abstract][Full Text] [Related]
8. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
Renau TE
Curr Opin Investig Drugs; 2004 Jan; 5(1):34-9. PubMed ID: 14983971
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T
Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast Altana Pharma.
Reid P
Curr Opin Investig Drugs; 2002 Aug; 3(8):1165-70. PubMed ID: 12211409
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
13. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Kodimuthali A; Jabaris SS; Pal M
J Med Chem; 2008 Sep; 51(18):5471-89. PubMed ID: 18686943
[No Abstract] [Full Text] [Related]
14. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
15. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
17. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
Barone FC; Barton ME; White RF; Legos JJ; Kikkawa H; Shimamura M; Kuratani K; Kinoshita M
Pharmacology; 2008; 81(1):11-7. PubMed ID: 17726343
[TBL] [Abstract][Full Text] [Related]
19. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
20. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]